Watch This Into the Open: See Why (MDCX) Has Our Full Focus Right Now

Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on Behalf of Medicus Pharma Ltd. Paul Prescott Puts (MDCX) Back At The Top Of This Morning's Watchlist—Tuesday, December 30, 2025 Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Pull Up (MDCX) While It's Still Early… December 30, 2025 Watch This Into the Open | See Why (MDCX) Has Our Full Focus Right Now Dear Reader, This story just took a sharp turn—and it's unfolding faster than most people realize. Artificial intelligence is no longer just a headline in this narrative. It's starting to look like a real tactical edge. Last week, Medicus Pharma Ltd. (NASDAQ: MDCX) revealed plans to roll out AI-driven clinical data analytics across its pipeline, beginning with its late-stage Teverelix program—an approach designed to make clinical execution sharper, faster, and far more data-driven. This isn't "AI for show." This is AI aimed directly at the pressure points that decide whether a clinical program moves cleanly forward… or gets bogged down—things like smarter site selection, tighter patient targeting, and better enrollment forecasting. And the timing couldn't be more interesting, because that AI update came right on the heels of another major milestone: (MDCX) also confirmed full enrollment of all 90 patients in its U.S. Phase 2 SkinJect study—setting the stage for topline results expected in Q1 2026. When milestones and strategy upgrades start stacking this tightly, momentum tends to follow. And that's exactly why (MDCX) just forced its way back onto our radar heading into Tuesday morning, December 30, 2025. But keep in mind, (MDCX) is working with an ultra-thin float of under 8M shares according to MarketWatch. When companies have small floats like this, the potential exists for big moves if demand begins to shift. Earlier this month, (MDCX) made an approximate 34% move in under 24 hours, from around $1.68 on December 3 to $2.26 on December 4. Add in insider ownership north of 30%—the kind of alignment that often signals confidence behind the scenes—and you can see why momentum watchers are paying attention again. All signs point to a setup worth a closer look. Analyst Targets Suggests 1,700% Upside Potential From Recent Range… Multiple market outlets, including Benzinga, MarketWatch, and TipRanks, have reported that D. Boral Capital analyst Jason Kolbert recently set a $27 target on (MDCX), suggesting 1,700% upside potential from its recent $1.50 range. That's not the only target now in play. Brookline Capital's Kumaraguru Raja raised his target from $12 to $20, which suggests 1,200% upside potential. While Maxim Group's Jason McCarthy's $12 target suggests 700% upside potential from current levels. Following its recent acquisition of Antev Limited, (MDCX) has expanded into two late-stage therapeutic programs addressing major clinical needs. With analyst coverage, regulatory progress, and technical momentum all converging, (MDCX) stands out as one of the biotech names to watch heading into this morning's session. FDA Clears Streamlined Path for SkinJect's Next Phase Medicus Pharma Ltd. (NASDAQ: MDCX) received positive Type C meeting feedback from the U.S. FDA for its SkinJect program—a dissolvable microneedle patch being developed to non-invasively treat basal cell carcinoma (BCC). The agency confirmed that the program may follow the streamlined 505(b)(2) pathway, potentially reducing both cost and development time, and also offered guidance on study design, endpoints, and formulation improvements, including an adhesive layer and applicator system. (MDCX) is advancing two Phase 2 trials: SKNJCT-003 in the U.S., now over 75% enrolled following a strong interim readout, and SKNJCT-004 across six clinical sites abroad. Enrollment for SKNJCT-003 is expected to complete before the end of Q4 2025, with an End-of-Phase-2 FDA meeting targeted for Q1 2026. The company estimates the market for non-invasive BCC treatments could approach $2B annually. Executive Chairman and CEO Dr. Raza Bokhari noted that the FDA's feedback "marks an important step toward establishing SkinJect as a potential first-in-market, non-invasive therapy for BCC," reinforcing growing confidence as development advances. (MDCX) Opens New Pathway for Patients With Compassionate Use Partnership Medicus Pharma Ltd. (NASDAQ: MDCX) announced a collaboration with the Gorlin Syndrome Alliance (GSA) to pursue a compassionate use pathway for its investigational SkinJect™ microneedle patch in patients with Gorlin Syndrome, a rare genetic condition affecting roughly 1 in 31,000 people worldwide. The partnership will jointly advance an Expanded Access IND Program with the FDA, allowing eligible patients with multiple or inoperable basal cell carcinomas to access SkinJect™ under physician supervision. The initiative also aims to collect real-world safety data while incorporating patient insights into ongoing development. Executive Chairman and CEO Dr. Raza Bokhari noted that the collaboration reflects (MDCX)'s mission to bring targeted innovation to conditions with significant unmet medical needs. First Patient Treated in UAE Marks Key Milestone in Global Phase 2 Expansion Just this week, Medicus Pharma Ltd. (NASDAQ: MDCX) announced that its first patient has been treated in the UAE SKNJCT-004 Phase 2 study for its SkinJect program—designed to non-invasively treat basal cell carcinoma (BCC). Cleveland Clinic Abu Dhabi is serving as the principal investigator, with additional recruitment planned across five major regional hospitals including Sheikh Shakbout Medical City and American Hospital Dubai. The study will enroll 36 participants across six UAE sites, coordinated by Insights Research Organization and Solutions (IROS), a member of the M42 healthcare portfolio. According to Dr. Raza Bokhari, Executive Chairman and CEO, this milestone "marks an important step in expanding Medicus's clinical footprint beyond the U.S.," underscoring the company's push to position SkinJect as a potential first-in-market non-invasive treatment for BCC—a global condition representing more than $2B in annual market potential. Teverelix Opens A $6B Clinical Expansion Lane For (MDCX) Medicus Pharma (NASDAQ: MDCX) has completed its acquisition of Antev Limited, gaining control of Teverelix trifluoroacetate, a next-generation GnRH antagonist in late-stage development for both acute urinary retention (AURr) and high cardiovascular-risk prostate cancer. The move broadens (MDCX)'s clinical scope into two therapeutic areas with a combined $6B market potential. Teverelix is designed for dual use: in AURr, a condition with high recurrence rates, it aims to become the first product to prevent relapse, supported by an FDA-cleared Phase 2b study of 390 patients. In prostate cancer patients with elevated cardiovascular risk, it is being evaluated in another FDA-cleared Phase 2b trial as a potentially safer alternative to conventional therapies. The acquisition also adds leadership depth, with veteran pharma executive Patrick J. Mahaffy joining the board. Together, the expanded pipeline and strengthened leadership put (MDCX) in position to reshape care across two areas of pressing medical need. Fresh Headlines Driving The (MDCX) Story Forward Dec 22, 2025 – AI-Driven Clinical Analytics Initiative Announced (MDCX) signed a non-binding LOI with Reliant AI to develop an AI-powered platform to support more efficient clinical trials, starting with Teverelix in 2026. Dec 15, 2025 – Phase 2 SkinJect Trial Fully Enrolled (MDCX) completed enrollment of all 90 patients in its U.S. Phase 2 SkinJect study, with topline results expected in Q1 2026 and an FDA EOP2 meeting targeted for H1 2026. Dec 01, 2025 – Appointment of Carolyn Bonner as Chief Financial Officer (MDCX) appointed President Carolyn Bonner as CFO, strengthening leadership as the company scales its clinical and regulatory execution. Nov 24, 2025 – Company Highlights Expanded Innovation Across Skin and Prostate Cancer Programs (MDCX) released an update highlighting continued progress across SkinJect and Teverelix, reinforcing its expanding clinical footprint and multi-program strategy. Nov 17, 2025 – FDA CNPV Application Filed for SkinJect (SKNJCT-003) (MDCX) submitted a CNPV application for SkinJect, aiming for potential 1–2 month FDA review while emphasizing national-priority alignment, including rare-disease relevance. Nov 14, 2025 – Q3 2025 Corporate Update & Financial Highlights (MDCX) reported clinical progress across SkinJect and Teverelix, expanded trial activity across multiple regions, and improved its balance sheet with $10.4M in new capital. 7 Factors Putting (MDCX) At The Top Of This Morning's Watchlist —Tuesday, December 30, 2025 1. Limited Float: with fewer than 8M shares available, (MDCX)'s small float has the potential for big moves if demand begins to shift. 2. Analyst Coverage: multiple firms have issued targets, from $12, $20 and up to $27, for (MDCX) that suggest roughly 700% to 1,700% upside potential from its recent range. 3. Recent Momentum: the chart for (MDCX) showcases an approximate 34% move in under 24 hours last week. 4. Insider Confidence: leadership continues to hold more than 35% of (MDCX)'s float, reinforcing long-term confidence behind the scenes. 5. AI Integration: recent plans to deploy AI-driven clinical analytics place (MDCX) among a small group of companies applying advanced data intelligence to improve trial execution and efficiency. 6. Phase 2 Milestone: full enrollment of 90 patients in the SkinJect Phase 2 study positions (MDCX) ahead of expected topline results targeted for Q1 2026. 7. Regulatory Boost: recent FDA Type C feedback has given (MDCX)'s SkinJect program a clearer and potentially faster 505(b)(2) route. All seven factors point to one conclusion—(MDCX) is entering a decisive stretch. With multiple potential catalysts aligning across its pipeline, this morning stands out as a moment to keep (MDCX) at the top of your radar. Pull Up (MDCX) While It's Still Early… With all of these forces stacking at once, (MDCX) sits in a rare position—one shaped by a float under 8M shares, a chart that has already produced multiple sharp overnight moves, and analyst targets stretching as high as $27 from its recent $1.50 range, which suggest over 700% to 1,700% upside potential. Add in leadership holding more than a third of the float, fresh FDA alignment on a streamlined regulatory path, expanding Phase 2 activity across three regions, and a broadened pipeline now anchored by two late-stage programs… and it becomes clear why this name refuses to drift quietly into the background. (MDCX) is our main focus this morning. It's worth pulling up while it's still early Keep an eye out for my next update, it could hit any moment. Sincerely, Paul Prescott Co-Founder & Managing Editor Street Ideas Newsletter Street-Ideas.com ("Street-Ideas" or "SI" ) is owned by 147 Media LLC, a single member limited liability company. Data is provided from third-party sources and SI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between 147 Media LLC and TD Media LLC, 147 Media LLC has been hired for a period beginning on 12/29/2025 and ending on 12/30/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, 147 Media LLC has been paid six thousand eight hundred USD ("Funds"). To date, including under the previously described agreement, 147 Media LLC has been paid fifty six thousand eight hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither 147 Media LLC, TD Media LLC and their member own shares of (MDCX:US). Please see important disclosure information here: https://street-ideas.com/disclosure/mdcx-Zw3JB/#details

Street Ideas | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446 Unsubscribe Update Profile | Constant Contact Data Notice Sent by paul@street-ideas.com